TSBX — Turnstone Biologics Income Statement
0.000.00%
Last trade - 00:00- $8.10m
- -$20.83m
Annual income statement for Turnstone Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 101 | 73.3 | 19.3 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 68.3 | 105 | 78.3 | 72.5 |
| Operating Profit | 33 | -31.6 | -59 | -72.5 |
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 33.7 | -30.7 | -55.5 | -70.8 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 33.3 | -30.8 | -55.2 | -70.8 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 33.3 | -30.8 | -55.2 | -70.8 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 3.48 | -31 | -55.2 | -70.8 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.157 | -1.4 | -4.67 | -3.06 |
| Dividends per Share |